TouchIMMUNOLOGY were delighted to talk to Ken Kato at ASCO’s virtual Gastrointestinal Cancers Symposium 2021 to discuss the potential role of nivolumab in the treatment of gastrointestinal cancers, and how the identification of biomarkers is key to improve clinical response.
For more information on the 5-year follow-up data presented at ASCO’s Gastrointestinal Cancer’s Symposium, please click here.
Questions
- What is known about the immunological effects of nivolumab treatment and what remains to be elucidated? (0:31)
- What progress has been made in identifying robust biomarkers associated with clinical response to nivolumab? (2:00)
Disclosures: Ken Kato has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
